Concerto Biosciences CEO Cheri Ackerman (L) and CSO Jared Kehe
'Rulebook of microbial ecology': Pianists launch Concerto to treat eczema, protect crops and get rid of BO
The microbiome world, at least in drug R&D, has had some hiccups this year, with Flagship’s Kaleido Biosciences shutting down and DermBiont pivoting away from …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
